Baird maintains Twist Bioscience at Outperform, lowers price target to $135 from $187

Baird retained its Outperform rating for Twist Bioscience but reduced its price target from $187 to $135, a 27.8% decrease. This implies an 18.2% upside from the Nov 12 close of $114.22, according to the firm.

Original reporting
Published Nov 13, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Baird maintains Twist Bioscience at Outperform, lowers price target to $135 from $187 — source image
Decision brief

The 30-second read

$TWSTBearishMed
01

Why it matters

The downgrade may trigger short-term price decline and influence peer sentiment.

02

Market read

Analyst target cut is a fresh piece of information that could affect trading decisions on TWST.

03

What to watch

Potential upcoming product launches or partnerships not reflected in the target revision.

Relevance 7/10Novelty 7/10Timing: today

Background

Baird Research provides equity research coverage for Twist Bioscience, a synthetic biology company.

Company-level read

Ticker impact

$TWSTBearishHigh confidence
Context

Baird lowered Twist Bioscience's price target to $135 from $187.

Expected impact

likely downward pressure as investors reassess valuation.

Evidence & confidence

A 27.8% target reduction signals weaker growth outlook, prompting sell pressure.

Market effects

May affect other synthetic biology stocks as analysts reassess sector valuations.

Limited to US biotech market.

Low global impact.

Counterpoint

Some investors may view the target cut as an entry point if they believe the market overreacted.

Key entities

  • Twist Bioscience

    Synthetic biology firm providing DNA synthesis services.

  • Baird

    Equity research firm issuing the price target revision.

Related articles

$TWSTHighAI 8/10

Canaccord cuts Twist Bioscience stock price target on lower revenue outlook

Canaccord reduced Twist Bioscience's (TWST) price target to $150 from $205, citing lower long-term revenue estimates. The company's Q4 results beat expectations, with revenue up 28% YoY to $126.6M. Twist provided fiscal 2027 guidance ahead of consensus but expects slower AI-enabled drug discovery revenue growth. Jefferies also lowered its target to $125, maintaining a Hold rating. TWST shares are down in premarket trading.

$TWSTHighAI 8/10

Twist Bioscience Corporation Q4 2026 Earnings Call Summary

Twist Bioscience reported positive adjusted EBITDA in Q4 2026, with revenue growth driven by a 175% YoY increase in AI drug discovery. The company expects $550M-$560M revenue in 2027, with $100M from AI drug discovery. It plans $150M in CapEx over two years to support future growth. Management highlighted structural advantages and strategic initiatives in AI and nucleic acid therapeutics.

$TWSTMedAI 8/10

Twist Bioscience Q4 Earnings Call Highlights

Twist Bioscience reported shipping 401,000 genes in Q4 and 1.3 million for the year. AI drug discovery revenue rose 175% to $59.1M. The company plans to expand capacity with 16 DNA writers and invest $150M in capital expenditures. Twist expects fiscal 2027 revenue of $130M-$132M in Q1 and positive adjusted EBITDA.

$TWSTMedAI 8/10

Twist Bioscience earnings analysis: questions answered and next catalysts

Twist Bioscience (TWST) reported FY2026 Q4 earnings on Nov 12, 2026, beating EPS and revenue estimates. Despite this, shares fell 7.90% to $112.91. Revenue grew 28% YoY to $126.6M, and the company achieved positive adjusted EBITDA of $2.2M. Management provided FY2027 guidance of $550M–$560M in revenue, above consensus. Concerns include valuation, capital intensity, and reliance on AI drug discovery orders. Next catalysts include Q1 FY2027 results and AI updates.

$TWSTMed

Twist Bioscience (TWST) Q4 2026 Earnings Call Transcript

Twist Bioscience reported Q4 2026 revenue of $126.6M, up 28% YoY, and full-year revenue of $460M, exceeding guidance. Adjusted EBITDA turned positive at $2.2M. The company highlighted growth in AI drug discovery, with revenue up 175% YoY, and expanded manufacturing capacity to meet demand. Twist's platform enables custom DNA manufacturing at scale, serving healthcare and research industries.